Cleavage and polyadenylation specificity factor subunit 1 (1360-1369)

Cleavage and polyadenylation specificity factor subunit 1 (1360-1369) is a synthetic peptide fragment derived from the C-terminal region of the CPSF1 protein, an essential component of the eukaryotic pre-mRNA 3'-end processing machinery. This peptide corresponds to amino acid residues 1360 through 1369 of CPSF1, a subunit that plays a pivotal role in the recognition of polyadenylation signals and the assembly of the cleavage and polyadenylation complex. As a research tool, the peptide enables targeted investigation into the molecular interactions and regulatory mechanisms underlying mRNA maturation, gene expression control, and post-transcriptional modification. Its defined sequence and structural features make it highly relevant for studies focusing on RNA processing, protein-protein interactions, and the functional dissection of multi-component ribonucleoprotein complexes.

Epitope mapping: The CPSF1 (1360-1369) peptide is widely utilized in epitope mapping studies, allowing researchers to define antibody recognition sites within the CPSF1 protein. By using this synthetic fragment, investigators can assess the specificity and affinity of antibodies raised against CPSF1, facilitating the development and validation of immunoassays, western blot protocols, or immunoprecipitation techniques. This targeted approach supports the generation of high-quality reagents for the detection and quantification of endogenous CPSF1 in diverse biological samples.

Protein interaction analysis: As a discrete segment of the CPSF1 protein, the peptide serves as a valuable probe in protein-protein interaction assays. Researchers employ the peptide in pull-down experiments, surface plasmon resonance, or microscale thermophoresis to elucidate binding partners and interaction domains relevant to the assembly and regulation of the cleavage and polyadenylation complex. Such studies advance understanding of how CPSF1 coordinates with other factors like CPSF subunits, symplekin, and poly(A) polymerase in the context of mRNA 3'-end formation.

Post-translational modification research: The specific amino acid sequence represented by residues 1360-1369 is amenable to in vitro modification studies, enabling detailed analysis of phosphorylation, acetylation, or ubiquitination events. By subjecting the peptide to modifying enzymes or chemical reagents, scientists can systematically investigate the impact of these modifications on CPSF1 function, complex assembly, and regulatory signaling. These insights are critical for unraveling mechanisms that fine-tune mRNA processing in response to cellular cues.

Structural biology: The defined structure of the CPSF1 (1360-1369) peptide facilitates its use in structural biology applications, including NMR spectroscopy and crystallography. Researchers can employ the peptide as a model system to dissect the conformational properties of the C-terminal region of CPSF1 or to study its mode of interaction with nucleic acids and protein partners. Such structural insights contribute to a more comprehensive understanding of the dynamic architecture of the cleavage and polyadenylation machinery.

Peptide-based assay development: The synthetic peptide is also applied in the development and optimization of peptide-based assays for high-throughput screening or mechanistic studies. Its well-characterized sequence allows for the design of assays that monitor enzymatic activity, binding specificity, or inhibitor screening relevant to pre-mRNA processing pathways. These assays support both basic research and early-stage drug discovery efforts targeting RNA maturation and gene regulation processes.

1. Novel Peptide-Based PD1 Immunomodulators Demonstrate Efficacy in Infectious Disease Vaccines and Therapeutics

2. Olfactory receptor based piezoelectric biosensors for detection of alcohols related to food safety applications

3. Myotropic activity and immunolocalization of selected neuropeptides of the burying beetle Nicrophorus vespilloides (Coleoptera: Silphidae)

4. Immune responses to homocitrulline-and citrulline-containing peptides in rheumatoid arthritis

5. Spatiotemporal delivery of nanoformulated liraglutide for cardiac regeneration after myocardial infarction